| Budget Amount *help |
¥46,280,000 (Direct Cost: ¥35,600,000、Indirect Cost: ¥10,680,000)
Fiscal Year 2020: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2019: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2018: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2017: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2016: ¥12,090,000 (Direct Cost: ¥9,300,000、Indirect Cost: ¥2,790,000)
|
|---|
| Outline of Final Research Achievements |
In respiratory diseases, there are several disorders to which very few pharmaceutical agents are currently effective. These disorders include ARDS, IPF, COPD and lung cancer. Recently, new research tools such as genetically-engineered mice have been widely used to study molecular mechanisms underlying human disorders. The purpose of this study is to investigate mechanism of respiratory diseases and develop novel therapeutics using these up-to-date cellular and molecular techniques including genetically-engineered mice. Our observations suggest that this strategy might provide a novel therapeutic approach to respiratory disorders such as ARDS, IPF and COPD and lung cancer.
|
